Skip to Content
Søk Menu

EHA24: LBA – Potential Frontline Treatment for Elderly Patients with Untreated Mantle Cell Lymphoma

Just released at this year’s EHA congress, this late-breaking abstract shows the promising efficacy and safety of acalabrutinib combined with bendamustine and rituximab for elderly patients with untreated mantle cell lymphoma.

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relatert innhold

Several Trials Showed Improvements in the Treatment of Multiple Myeloma

/ BestPractice Nordic
EHA24Myelomatose

EHA 2024: One of the Most Important for Many Years

/ BestPractice Nordic
EHA24Lymfom

CLL: Needs At Least 10 Years of Follow-Up for Clinical Trials

/ BestPractice Nordic
CLLEHA24

The Development of New Treatment Options within AML Is Slower Than in Other Disease Areas within Hematology

/ BestPractice Nordic
AMLEHA24

New Data from EHA Shared and Discussed at Danish Evening

/ Jan Andreasen
EHA24
Maria Eugenia Chollet

Promising Avenues for the Development of Personalized Treatment for FVII Deficiency

/ Maria Eugenia Chollet
EHA24 Play the Video 5:06
Hanne Norseth

Vaccinating Against Mutated RAS in Multiple Myeloma

/ Hanne Norseth
EHA24Myelomatose Play the Video 3:27
Sergio Martinez Høyer

An Excellent Target with a Wide Therapeutic Window in del(5q) Myeloid Malignancies

/ Sergio Martinez Høyer
EHA24 Play the Video 5:13
Frida Bugge Askeland

Treating MRD Relapse After First-Line Treatment May Prolong PFS and OS in Myeloma Patients

/ Frida Bugge Askeland
EHA24Myelomatose Play the Video 1:59
Back to top